Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.“[Cutaneous lupus erythematosus (CLE)], ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

When interferon treatment was being developed in the Soviet Union, this was effectively overlooked in the West during the cold-war era due to its concentration on the development of vaccines.

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study. “Dermatomyositis is a ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Dazukibart, an anti–interferon beta monoclonal antibody, showed potential in reducing dermatomyositis symptoms, with ...

Researchers at MedUni Vienna have developed a combination therapy using systemic interferon-I and topical imiquimod.